Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic
company focused on developing and marketing products to treat medical
conditions in the inflammatory, orthopedic, and cardiovascular areas,
announced today that it will report its financial results for the
quarter ended March 31, 2008 on Friday, May 9, 2008. C. Randal Mills,
Ph.D., President and Chief Executive Officer, will provide a company
update and discuss results via a webcast and conference call on Friday,
May 9, 2008 at 9:00 a.m. EDT. To access the web cast, visit the Investor
Relations section of the company's website at http://investor.osiris.com/events.cfm.
Alternatively, callers may participate in the conference call by dialing
(877) 397-0291 (U.S. participants) or (719) 325-4920 (international
participants).
A replay of the conference call will be available approximately two
hours after the completion of the call through May 23, 2008. Callers can
access the replay by dialing (888) 203-1112 (U.S. participants) or (719)
457-0820 (international participants). The audio replay passcode is
4062144. To access a replay of the webcast, visit the Investor Relations
section of the company's website at http://investor.osiris.com/events.cfm.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a leading stem cell therapeutic company
focused on developing and marketing products to treat medical conditions
in the inflammatory, orthopedic and cardiovascular areas. Osiris
currently markets and sells Osteocel®
for regenerating bone in orthopedic indications. Prochymal™
is being evaluated in Phase III clinical trials for three indications,
including acute and steroid refractory Graft versus Host Disease and
also Crohn's disease, and is the only stem cell therapeutic currently
designated by FDA as both an Orphan Drug and Fast Track product. Osiris
has also partnered with Genzyme Corporation to develop Prochymal™
as a medical countermeasure to nuclear terrorism and other radiological
emergencies. Prochymal is also being developed for the repair of heart
tissue following a heart attack and for the protection of pancreatic
islet cells in patients with type 1 diabetes. The Company’s
pipeline of internally developed biologic drug candidates under
evaluation also includes Chondrogen™ for
arthritis in the knee. Osiris is a fully integrated company, having
developed capabilities in research, development, manufacturing,
marketing and distribution of stem cell products. Osiris has developed
an extensive intellectual property portfolio to protect the company's
technology in the United States and a number of foreign countries
including 47 U.S. and 253 foreign patents owned or licensed. More
information can be found on the company's website, www.Osiris.com.
(OSIR-G)
Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements may generally be identified by the use of the
words "may," "will," "expects," "anticipates," "believes," "estimates,"
and similar expressions, and involve a number of risks and
uncertainties. For a variety of reasons, actual results may differ
materially from those described in or contemplated by any such
forward-looking statement. Consequently, the reader is cautioned to
consider all forward-looking statements in light of the risks to which
they are subject.
|